A214450 Stock Overview
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
PharmaResearch Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩113,300.00 |
| 52 Week High | ₩158,200.00 |
| 52 Week Low | ₩86,800.00 |
| Beta | 0.36 |
| 1 Month Change | 13.53% |
| 3 Month Change | 0.80% |
| 1 Year Change | 12.18% |
| 3 Year Change | 61.86% |
| 5 Year Change | 173.34% |
| Change since IPO | -1.05% |
Recent News & Updates
Recent updates
PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25Shareholder Returns
| A214450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -12.5% | 0.3% | -0.4% |
| 1Y | 12.2% | 5.7% | 4.5% |
Return vs Industry: A214450 exceeded the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A214450 exceeded the KR Market which returned 4.5% over the past year.
Price Volatility
| A214450 volatility | |
|---|---|
| A214450 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A214450 has not had significant price volatility in the past 3 months.
Volatility Over Time: A214450's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 354 | Sang-Soo Jung | www.pharmaresearch.co.kr/kor/ |
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask.
PharmaResearch Co., Ltd. Fundamentals Summary
| A214450 fundamental statistics | |
|---|---|
| Market cap | ₩1.16t |
| Earnings (TTM) | ₩76.55b |
| Revenue (TTM) | ₩261.01b |
15.1x
P/E Ratio4.4x
P/S RatioIs A214450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214450 income statement (TTM) | |
|---|---|
| Revenue | ₩261.01b |
| Cost of Revenue | ₩70.75b |
| Gross Profit | ₩190.26b |
| Other Expenses | ₩113.71b |
| Earnings | ₩76.55b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.50k |
| Gross Margin | 72.89% |
| Net Profit Margin | 29.33% |
| Debt/Equity Ratio | 7.2% |
How did A214450 perform over the long term?
See historical performance and comparison